We ARE AN industry-leading company that is transforming the world of digital therapeutics.

Brian Harris

CEO and Founder

Brian Harris

CEO and Founder

Brian, the co-founder and CEO of MedRhythms, Inc., is passionate, motivated, and committed to bringing high-quality care to everyone across the globe. This vision inspired the creation of MedRhythms and has allowed the company to expand and evolve to better serve patients. After completing his undergraduate degree in Psychology in 2011, Brian Harris received his masters in Music Therapy.

Harris has since become a Board-Certified Music Therapist with specialized training in Neurologic Music Therapy (NMT). He later received advanced training in the field, becoming one of only 250 people in the world with the distinction of NMT Fellow. Harris was hired as the first NMT at Spaulding Rehabilitation Hospital in Boston, where, in 2015, he founded the clinical division of MedRhythms.

With his continued leadership, this business has grown into the most comprehensive NMT program in the country. Since 2013, Harris has delivered over 100 presentations on the clinical application of music at venues around the world, including Harvard Medical School, the American Congress of Rehabilitation Medicine, Alpert Medical School at Brown University, the American Academy of Neurological Surgeons, and Stanford Medical Center.

He is the CEO of MedRhythms and lives in Portland, Maine, where he works at the headquarters for the company's recently launched medical device division. In his spare time he enjoys playing ping pong, watching college basketball and traveling.

Owen McCarthy

President and Founder

Owen McCarthy

President and Founder

Owen is the co-founder and President of MedRhythms Inc., which he intends to lead with compassion and a commitment to excellence. He is determined to provide patients across the globe with the services necessary to recover their walking ability and regain their independence. Owen started MedRhythms as an experienced entrepreneur with a MBA degree from Harvard Business School.

Prior to matriculating at Harvard, Owen was an engineering student at the University of Maine. He was among the top students at the university and was named the top engineering student in the class of 2010. His entrepreneurial experience officially began in 2013 when he served on the founding team for the 3D printing company Voxel8, where he worked in business development. Prior to Voxel8, Owen worked as an intrapreneur in sales at Ashland Inc., doubling the size of a new focus area of the company.

Owen additionally serves as the Chair of the University of Maine Board of Visitors, where he serves as a strategic advisor to the President of the university. On the weekends, Owen is an avid basketball player, reluctant runner, and a passionate University of Maine Black Bear fan from his home in Gorham, Maine.

David Guerette

Software Engineer

David Guerette

Software Engineer

David Guerette is a lifelong musician and has worked at the intersection of music and technology since graduating from Brandeis University in 2008. At MedRhythms, he architects and builds MedRhythms' HIPAA-compliant data storage and processing pipeline. He also applies his music composition and audio production domain knowledge to create music analysis tools and produce custom Rhythm Assist content.

His experience includes providing technical support for music recording software at Cakewalk, producing multimedia content at the NPR show “From the Top,” building high-traffic web services in advertising, and film scoring. In his spare time you'll find him finding ways to make new sounds out of old synthesizers and drum machines.

Eric Richardson

VP of Product Development

Eric Richardson

Software Engineer

Eric Richardson has worked in the digital media and audio technology industries for over twenty-five years, during which time he honed his talent for business development, strategic marketing, and product management for several international public companies. Eric’s executive responsibilities included high value account development, R&D team leadership, and strategic partner relationships.

Eric is currently a member of the software engineering team at MedRhythms, and contributes his extensive knowledge of music cognition and mobile application engineering. He is passionate about music and is thrilled that it can improve people’s lives in a meaningful way.

Previously, Eric was president of Fwave, Inc., a software product development company that created EnTrainer, a mobile app for musical running, as well as a cybersecurity simulation platform for global financial institutions. Eric graduated with a B.A. from Dartmouth College, received a diploma in Audio Engineering and Music Production from Berklee College of Music and is a Masters candidate in Digital Musics at Dartmouth College.

Eric gets wet as a competitive sailor and wishes ski seasons lasted a little bit longer. He can sometimes be seen playing bass in his jazz quartet.

Alex Kalpaxis

CTO

Alex Kalpaxis

CTO

For over twenty years Alex Kalpaxis has been designing software to solve problems for companies with a global reach. At a young age, he became the VP of Technology at Bankers Trust Company (now Deutsche Bank), where he defined the global Banker's Trust Technical Architecture (BTA) in collaboration with key technology and business personnel. Here, Kalpaxis co-created the first real-time global trading system on Wall Street, the Broadgate Information Data Distribution System (BIDDS).

Kalpaxis has created, patented, and developed several breakthrough products for the commercial and medical marketplaces, and he has extensive experience in bringing hardware and software products to market. These products range from small-scale, embedded equipment suites to enterprise-class software systems. Some of these have generated more than $100 million in revenue. He has held positions in public companies ranging from Chief Scientist to Chairman/CTO and has managed teams of over 150 people globally with budgets in excess of $30 million.

In 2007, he co-founded 24eight, LLC and became the owner and CTO of the company. With his tenure as CTO at 24eight, LLC, Alex Kalpaxis has created a proprietary scalable platform technology, which applies low-cost, standards-based, commercial off-the-shelf (COTS) hardware and software to create a product suite of sensor devices. The sensors utilize MEMS technology and bio-sensing materials – including accelerometers and nano-piezo-resistive non-woven fabric pressure sensors – to capture data for 3-dimensional motion, pressure/force and distribution thereof, spatial locality, and temporal parameters. The sensors can also monitor certain physiological parameters, including EKG, heart rate, respiratory rate, and skin-surface temperature. These sensors are then combined with cognitive analytic algorithms and wireless mesh networking capabilities to create an event-based capture system.

Lauren Steidl

Customer Development and Marketing

Lauren Steidl

Customer Development and Marketing

Lauren Steidl works in Customer Development and Marketing at MedRhythms. She graduated last spring from Princeton University, where she majored in the History of Science with a focus in medical history. After her sophomore year at Princeton, she was selected for the Harvard Orthopedic Trauma Undergraduate Research Internship program, an 8 week clinical summer research internship. The following summer, Lauren conducted breast cancer research for an Immunology Lab at the Massachusetts General Hospital. In her free time, Lauren enjoys running, exploring Maine, and singing in a local rock band.


Advisory Board

Ron Hirschberg

M.D at MGH and Spaulding, Movement Clinic

Ron Hirschberg

M.D at MGH and Spaulding, Movement Clinic

Dr. Ron Hirschberg is a physiatrist who works in acute inpatient care at Massachusetts General Hospital. Dr. Hirschberg specializes in trauma rehabilitation with emphasis on traumatic brain injury (TBI) spinal cord injury (SCI) and polytrauma. His experience and interests are in continuum of care for rehab and recovery, general neurorehabilitation in acute and post acute settings, in addition to the music-brain interface and neurologic music therapy (NMT).

Current research interests include TBI - with projects in recovery and treatment with low-level-laser-therapy (LLLT), severe TBI prognosis and diagnosis with work in functional MRI, EEG including response to music stimuli - and early mobilization in the intensive care unit.

Lou Awad

Wyss Institute and founder of BU’s NeuromotorRecovery Laboratory

Lou Awad

Wyss Institute and founder of BU’s Neuromotor Recovery Laboratory

Lou Awad is a movement scientist with clinical training as a physical therapist. He is currently an Associate Faculty Member at the Wyss Institute for Biologically Inspired Engineering at Harvard University, where he received his Postdoctoral Training. Awad founded the Neuromotor Recovery Laboratory at Boston University and is an Assistant Professor in BU’s Department of Physical Therapy & Athletic Training.

Additionally, Awad is a Research Faculty Member at Spaulding Rehabilitation Hospital Stroke Research and Recovery Institute. His research is grounded in a multi-modal evaluation framework that spans the clinical, biomechanical, and physiological domains.

He has led and contributed to studies that have spanned the translation continuum, focusing on the discovery and evaluation of novel interventions and wearable rehabilitative technology.

David Storto

President of Spaulding Rehabilitation Hospital

David Storto

President of Spaulding Rehabilitation Hospital

David E. Storto is the President of Partners Continuing Care and the Spaulding Rehabilitation Network. Under Mr. Storto's leadership since 1998, PCC has grown and been developed as the fully integrated non-acute care services division of Partners HealthCare based in Boston, Massachusetts. PCC includes two inpatient rehabilitation hospitals with 23 outpatient centers, two long-term acute-care hospitals, and three skilled nursing facilities, together recognized as the SRN. Spaulding Rehabilitation Hospital is the highly ranked and internationally recognized flagship of the SRN and is home to the Harvard Medical School's Department of Physical Medicine and Rehabilitation.

Prior to joining Partners and Spaulding, Mr. Storto was the Executive Vice President, Chief Operating Officer and a member of the Board of Directors of the Rehabilitation Institute of Chicago (RIC). Mr. Storto served in numerous capacities during his 18-year tenure at RIC, including social worker, Director of Admissions and Marketing, General Counsel and Corporate Secretary, and Vice President of Planning. During this time, he became an expert in operational management, program development, governance and strategic planning in rehabilitation facilities.

Mr. Storto received his undergraduate degrees from the University of Michigan, Ann Arbor, with distinction, in 1976 and a Masters Degree in Social Service Administration from the University of Chicago in 1978. He received his Juris Doctor from the Loyola University of Chicago School of Law in 1986.

Mr. Storto is married to Shelley Mogil and they live in Boston, Massachusetts. They have two children Max and Mara. Outside of work and family, Mr. Storto is a marathon runner who loves to cook, sing karaoke, and travel.

Richard Mileski

Former U.S. VP of Quality at Barr Pharmaceuticals

Richard Mileski

Former U.S. VP of Quality at Barr Pharmaceuticals

Richard Mileski is a pharmaceutical industry professional with over 25 years of diversified quality, technical, and executive experience. A creative self-starter with strong problem solving skills, Richard has demonstrated leadership at all levels within organizations. Currently, Richard works as a pharmaceutical consultant who provides due diligence audits, support, and follow-up for Private Equity firms looking to invest in early stage pharmaceutical and related industries. He has extensive knowledge of pharmaceutical manufacturing, quality assurance, and regulatory compliance activities. He gained hands-on experience in solid dosage manufacturing facility start-up operations, and he was involved in ERP and IT Quality Systems selection and implementation. Before working as a pharmaceutical consultant, Richard served as the Vice President of Quality at Putney, Inc.

Jen Johansson

VP of Regulatory Affairs at Chrondrial Therapeutics

Jen Johansson

VP of Regulatory Affairs at Chrondrial Therapeutics

Jennifer Spokes Johansson has more than 20 years of pharmaceutical legal and regulatory experience. She is currently the Vice President of Regulatory Affairs and Counsel at Chondrial Therapeutics. Most recently, Jennifer served as the senior Vice President of Regulatory Policy and Counsel for Putney, Inc., where she was chair of the Generic Animal Drug Alliance and a member of the industry negotiation teams for the Animal Generic Drug User Fee Act and its reauthorization. Jennifer also served as Vice President of Regulatory Affairs and Counsel for Andrx (now Teva), the largest generic drug company in the world.

Before joining Andrx, she worked at the law firm of Patton Boggs (now Squire Patton Boggs) as an associate in a leading food and drug regulatory practice. Jennifer completed her undergraduate career at Duke University, where she graduated cum laude and with Distinction in Biology. She continued her education at Boston University School of Law and, while there, served as an editor of the Boston University Law Review and graduated magna cum laude. She is a member of the bars of Massachusetts and Washington, DC.

Michael Thaut

Founder, Academy of Neurologic Music Therapy & University of Toronto Professor

Michael Thaut

Founder of the Academy of Neurologic Music Therapy and University of Toronto Professor

Michael H. Thaut received his PhD in music with a cognate minor in movement science in 1983 and his masters in music 1980, both from Michigan State University. He also studied at the Mozarteum Music University in Salzburg, Austria. He holds a German Diploma degree in psychology/education. At Colorado State University (CSU) he was Professor Music since 1986-2015 and Director of the School of the Arts 2001-2010. He received a joint appointment as Professor of Neuroscience in 1998. He was Director of the Center for Biomedical Research in Music since 1994. Since 2016 he is Professor of Music with cross appointments in Neuroscience and Rehabilitation Sciences at the University of Toronto where he directs the Music and Health Research Collaboratory (MaHRC) and the Masters/PhD programs in Music and Health Sciences. He has been a Visiting Professor in medical and music schools around the world (Germany, Italy, USA, Japan), and 2010-2012 was chancellor of the SRH University System in Germany.

Over the past decade he and his co-investigators have received over 4 million in prestigious and highly competitive research funding from the US National Institutes of Health (NIH) and private foundations. He has received the American Music Therapy Association’s National Research Award 1993 and its National Service Award 2001. His recent publication (with Volker Hoemberg), The Oxford Handbook of Neurologic Music Therapy (2014), was second overall in the British Medical Association (BMA) 2015 Book Awards for ‘Best New Book in Neurology’ (60 entries), an unprecedented achievement for a work in music therapy/medicine. Dr. Thaut has authored/co-authored about 250 scientific publications in multiple fields. His publications have appeared in journals like Frontiers in Human Neuroscience, Brain Sciences, Neuroimage, Music Perception, Biological Cybernetics, Movement Disorders, etc. His books have been translated into Korean, Japanese, and Chinese. He is globally in demand as a keynote speaker on music, brain, and neurorehabilitation.

His research career has been focused on the neural and psychophysical basis of music and rhythm perception and clinical application of music and rhythm to motor, speech/language, and cognitive training in neurologic disorders. He is the founder of the evidence-based treatment system of Neurologic Music Therapy whose certificate training has been endorsed by the World Federation of Neurorehabilitation. He is President of the International Society for Clinical Neuromusicology, Vice President of the International Society for Music and Medicine, a Management Board Member of the World Federation of Neurorehabilitation, and an elected Overseas Fellow of the Royal Society of Medicine (U.K.).

In addition to his groundbreaking work as a researcher and clinician, Dr. Thaut is an accomplished musician and violinist in the classical and folk genre, having toured and recorded extensively, especially in folk music. His anthology of European and North American Fiddle Music (Das grosse Fiddlebuch) has been in print since 1981.

 

Scott Wallace

Advisor, VP of Strategic Partnership at Optum Labs 

Scott Wallace

Advisor, VP of Strategic Partnership at Optum Labs

Scott Wallace is Vice President of Business Development at Optum Labs, an open collaborative research and innovation center. Optum Labs partners with industry stakeholders, leveraging healthcare big data, information assets, and tools to accelerate innovation and translate research into improved patient care.

Prior to joining Optum Labs in 2014, Scott worked at Alliance Life Sciences Consulting Group, Inc., where he focused on helping life science companies improve operational results within the commercial business space. As Vice President of Sales & Marketing, he was responsible for global sales and marketing efforts as well as business client relationships in the greater Boston area.

Scott also worked for IBM Healthcare & Life Sciences from 2002-2005 and again from 2007-2012 in sales leadership and management roles that were focused on driving client value through IBM’s entire product, service, and solution portfolio. From 2005-2007, Scott held the position of Vice President of Business Development at BG Medicine, an early stage Systems Biology research company. Here, he was responsible for all sales, marketing, and business development activities. Prior to 2002, Scott held a variety of sales leadership and business development positions at several companies in the Healthcare and Life Science industries.

Scott is passionate about coaching, mentoring, and building high-performance teams in the areas of business strategy and growth. These leadership qualities, along with his experience in advanced analytics, big data, and AI, have made Scott a valuable Advisory Board member. At MedRhythms, he provides strategic and practical guidance in the company’s development.

 

Board of Directors

Jean Hoffman

Board Member

Jean Hoffman

Board Member

Jean Hoffman founded, chaired the Board of Directors and led Putney as President and CEO from inception to a $200 million exit in April 2016. Ms. Hoffman developed the strategy, raised over $60 million in debt and equity and recruited the outstanding team that built Putney into America’s leading generic drug company for pets. Under her leadership, Putney’s R&D and Regulatory team received 47% of the dog and cat generic approvals by FDA from 2012-2015. The Company’s commercial team launched eleven veterinary approved products for pets, four of them first to market generic dosage equivalents. Putney had the highest product market shares of any U.S. generic veterinary company as well as the highest growth rate amongst all U.S. animal pharmaceutical companies.

In April 2016, Putney sold 100% of the company to Dechra Holdings US Inc., a subsidiary of Dechra Pharmaceuticals PLC for $200 million in cash.

Putney was Jean Hoffman’s second successful exit for a company she founded and built, after the acquisition of Newport Strategies, Inc. by Thomson Reuters (NYSE-TRI) in 2004. Newport built a global brand for its proprietary healthcare information technology (HIT) systems. Newport’s software developers delivered multiple generations of proprietary information systems that were adopted by customers on five continents and achieved an industry leading annual renewal rate of more than 85%.

Jean Hoffman has been honored with numerous awards, including being an EY Entrepreneur Of The Year™ 2014 Award winner in the life sciences category for New England.

Other honors include being inducted into NewSpring Capital’s CEO Hall of Fame in 2016 for outstanding investment returns; Deloitte’s 2013 North American Technology Fast 500; Inc. 5000 list of fastest growing private companies in the U.S., 2011 and 2013; Goldman Sachs Builders & Innovators Summit Honoring 100 Most Intriguing Entrepreneurs in 2012; and Best Places to Work in Maine, Society for HR Management, #1 in 2013; ranked in 2014 and 2012.

Bill McKee

Board Observer

Bill Mckee

Board Observer

Mr. McKee served as Chief Operating Officer and Chief Financial Officer at EKR Therapeutics, Inc., a private specialty pharmaceutical company until EKR was sold to Cornerstone Therapeutics Inc. Prior to that, Mr. McKee served as the Executive Vice President and Chief Financial Officer of Barr Pharmaceuticals, LLC, a subsidiary of Teva Pharmaceutical Industries Limited, a generic pharmaceutical company, and the successor entity to Barr Pharmaceuticals, Inc., a public specialty pharmaceutical company, which was acquired by Teva.

Mr. McKee was also Executive Vice President and Chief Financial Officer of Barr prior to its acquisition by Teva, after having served in positions of increasing responsibility at Barr until its acquisition. Prior to joining Barr, Mr. McKee served as Director of International Operations and Vice President, Finance at Absolute Entertainment, Inc., a private developer and marketer of entertainment software. Mr. McKee previously worked at Gramkow & Carnevale, CPA’s, an accounting firm, and also worked at Deloitte & Touche.

Mr. McKee serves on the board of directors of Agile Therapeutics, Inc., a public specialty biopharmaceutical company, Cerulean Pharma Inc., and previously served on the board of Auxilium Pharmaceuticals, Inc. until its acquisition. Mr. McKee received his B.B.A. from the University of Notre Dame.

Ray Pawlicki

Board Member

Ray Pawlicki

Board Observer

Ray joined the Healthcare industry in 2000 and subsequently became the Global CIO for Novartis Pharmaceuticals AG. based in Basel Switzerland. After eight years with Novartis, Ray returned to the US in 2008 and joined Biogen as their Chief Information Officer.

As a member of the Executive Committee, Ray was an active participant in growth and transformation of Biogen. Ray now resides in Boston, Massachusetts and has recently shifted his focus to board work.

Ray participates on various boards including Harvard Pilgrim Healthcare, UMass Memorial Healthcare, Berg Pharma, Nanowear, Boston Technology Research, Enginologi, and Rockstep. Ray has a degree in Computer Science from Montclair University and has participated in extensive executive education programs at Harvard University and IMD in Lausanne, Switzerland.

PETER WERTH

Board Member

Peter Werth

Board Member

Peter J. Werth founded Chemwerth, Inc. in 1982 and serves as its Chief Executive Officer and President. Mr. Werth has worked in the chemical side of the generic drug business from its inception in 1975 in the areas of Research & Development and Sales and Marketing. From 1965 to 1975, he served in R & D for Upjohn Pharmaceuticals (now Pfizer). Before starting ChemWerth, he served as Vice President of Sales and Marketing of US operations with Ganes Chemicals, a subsidiary of Siegfried Chemicals.

Mr. Werth is also a recognized philanthropist, establishing the Werth Family Foundation in 2001 to support higher education, children and human services, the arts and the environment. His philanthropy has touched the lives of thousands of people across the country and around the globe.

Mr. Werth earned a BS degree in Chemistry and Math from Kansas State College, and an MS degree in Organic Chemistry from Stanford University.

Brian Harris

Board Member

Owen McCarthy

Board Member